Viatris Inc traded at $13.05 this Friday March 27th, decreasing $0.32 or 2.39 percent since the previous trading session. Looking back, over the last four weeks, Viatris lost 16.88 percent. Over the last 12 months, its price rose by 50.35 percent. Looking ahead, we forecast Viatris Inc to be priced at 13.10 by the end of this quarter and at 11.95 in one year, according to Trading Economics global macro models projections and analysts expectations.
Viatris Inc. is a global healthcare company. The Company''s segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s ARV franchise. The Company’s portfolio comprises approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands and generics, including complex products. The Company operates manufacturing sites across worldwide that produce oral solid doses, injectables and complex dosage forms.